

# THE MOST COMPLETE RANGE OF CHROMOGENIC ASSAYS FOR HEPARIN

(Therapy monitoring - Drug testing, pharma)

## KINETICS/COMPETITIVE METHODS:

### Anti-Xa :

- The method of choice for the current testing of heparin in clinical samples.
- Can be used for UFH, LMWH (hybrid curve), Orgaran® or Arixtra®, on an extended range (0 to 2 IU/mL).
- Endogenous AT III present in the tested plasma.
- Assay variant with exogenous AT III.

### Anti-IIa

- The method of choice for testing heparin anti-IIa activity on a wide range of concentrations, without diluting the sample (0 to 6 IU/mL).
- Appropriate assay for testing drugs in purified systems or coated devices.
- Exogenous AT III supplied in the assay.

## TWO-STAGE METHODS:

### Anti-Xa :

- Working range 0 to 2 IU/mL in plasma (1:10), or 0 to 0.2 IU/mL in purified systems.
- The method of choice for testing heparin, in compliance with pharmacopoeias.
- Can be used for pentasaccharide (Arixtra®/Fondaparinux) and Orgaran®.
- Exogenous AT III supplied in the assay.

### Anti-IIa :

- Working range 0 to 1 IU/mL in plasma (1:25), or 0 to 0.04 IU/mL in purified systems.
- Highly sensitive; can be used for testing heparin, in compliance with pharmacopoeias.
- Working range can be adjusted through the dilution used.
- Exogenous AT III supplied in the assay.

*In compliance with the latest USP guidelines  
All assays can be used on laboratory automated instruments*

A full range of calibrators and controls (UFH/LMWH/Arixtra®/Orgaran®), established against the NIBSC International Standards for UFH and LMWH, are available

## Diagnosis of Heparin Induced Thrombocytopenia (HIT)



Diagnosis/Confirmation: IgG isotypes

Risk assessment : Total isotypes (IgGAM)

Research investigations (IgG, IgM, IgA)

Form AH108  
7-2009

and for Heparin complications of HIT  
ZYMUTEST HIA

**Diagnosis**

**Risk assessment**